Jose Carlos de la Flor

Antiproteinuric Response to Finerenone in Diabetic Kidney Disease: Responder and Non-Responder Subgroup Analysis of the FINDKDLATAM Study

Background/Objectives: Albuminuria is an early marker of kidney damage and an independent predictor of adverse outcomes, making its reduction a key therapeutic goal. Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, has demonstrated renal and cardiovascu...